Hoechst heats up arthritis-drug duel
Article Abstract:
Germany-based Hoechst AG's new arthritis drug Arava can slow the progression of joint damage in severe arthritis over 12 months, according to X-ray results presented in San Diego, CA. Arava is Hoechst's answer to Immunex Corp.'s Enbrel, which is viewed by scientists as a breakthrough because it blocks a critical immune molecule called tumor necrosis factor. Arava, an updated version of an old class of drugs, has similar side-effects and efficacy to a previous medicine called methotrexate. Hoechst's drug costs around $3,000 annually compared with $10,000 for the genetically engineered product of Immunex.
Comment:
Its new arthritis drug Arava can slow progression of joint damage in severe arthritis over 12 months, according to X-ray results
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
U.S. FDA panel backs two drugs for breast cancer
Article Abstract:
The first two drugs to show that they can lower the possibility of breast cancer in healthy women has won the approval of a scientific advisory panel with the US Food and Drug Administration (FDA). However, the panel warned that the drug has proven to be effective in combating breast cancer for only a few years. The drug's potency after that time is in doubt. Zeneca Group PLC's Nolvadex and Genentech Inc.'s Herceptin were the drugs that won approval.
Comment:
First two drugs to show that they can lower the possibility of breast cancer in healthy women wins approval of FDA panel
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Merck plans to buy Sibia for 81.4 million euros
Article Abstract:
Merck & Co. has reached an agreement to purchase Sibia Neurosciences Inc. for $87 million (81.4 million euros). The deal will strengthen Merck's attempts at developing nervous-system disorder medicines. La Jolla-based Sibia is known for its brain receptor research. Merck stated that it would pay $8.50 per share to acquire Sibia.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Credit Suisse bets on Latin America with Garantia. Merck sells stake in marketing deal for 870 million euros. Merck buys stake in U.S. biotech firm; drug maker bets on experimental therapies
- Abstracts: Employees at Dewe Rogerson await windfall after takeover. Meyer will pay 404.6 million euros for rival Graham
- Abstracts: British Airways plans to overhaul its fleet. Saatchi aims to raise profit margins
- Abstracts: Baan plans to slash work force by 20%. SAP pretax profit tops forecasts, spurring stock
- Abstracts: The French market for tobacco: company profiles: British American Tobacco (BAT) Holdings. The French market for tobacco: company profiles: Philip Moris Companies Inc